Literature DB >> 24018261

Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.

Miki Matsuo1, Longzhu Cui, Jeeyoung Kim, Keiichi Hiramatsu.   

Abstract

Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) spontaneously produces VISA cells within its cell population at a frequency of 10(-6) or greater. We established a total of 45 VISA mutant strains independently obtained from hVISA Mu3 and its related strains by one-step vancomycin selection. We then performed high-throughput whole-genome sequencing of the 45 strains and their parent strains to identify the genes involved in the hVISA-to-VISA phenotypic conversion. A comparative genome study showed that all the VISA strains tested carried a unique set of mutations. All of the 45 VISA strains carried 1 to 4 mutations possibly affecting the expression of a total of 48 genes. Among them, 32 VISA strains carried only one gene affected by a single mutation. As many as 20 genes in more than eight functional categories were affected in the 32 VISA strains, which explained the extremely high rates of the hVISA-to-VISA phenotypic conversion. Five genes, rpoB, rpoC, walK, pbp4, and pp2c, were previously reported as being involved in vancomycin resistance. Fifteen remaining genes were newly identified as associated with vancomycin resistance in this study. The gene most frequently affected (6 out of 32 strains) was cmk, which encodes cytidylate kinase, followed closely by rpoB (5 out of 32), encoding the β subunit of RNA polymerase. A mutation prevalence study also revealed a sizable number of cmk mutants among clinical VISA strains (7 out of 38 [18%]). Reduced cytidylate kinase activity in cmk mutant strains is proposed to contribute to the hVISA-to-VISA phenotype conversion by thickening the cell wall and reducing the cell growth rate.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24018261      PMCID: PMC3837870          DOI: 10.1128/AAC.00425-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  51 in total

1.  The allosteric regulation of pyruvate kinase.

Authors:  G Valentini; L Chiarelli; R Fortin; M L Speranza; A Galizzi; A Mattevi
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

2.  Vancomycin-resistant Staphylococcus aureus occurs in South Africa.

Authors:  V Ferraz; A G Dusé; M Kassel; A D Black; T Ito; K Hiramatsu
Journal:  S Afr Med J       Date:  2000-11

3.  The D-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes.

Authors:  A Peschel; C Vuong; M Otto; F Götz
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA).

Authors:  Mark C Enright; D Ashley Robinson; Gaynor Randle; Edward J Feil; Hajo Grundmann; Brian G Spratt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

5.  Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate.

Authors:  S Boyle-Vavra; R B Carey; R S Daum
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

6.  Vancomycin-intermediate Staphylococcus aureus in Korea.

Authors:  M N Kim; C H Pai; J H Woo; J S Ryu; K Hiramatsu
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

7.  Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin.

Authors:  G A Oliveira; A M Dell'Aquila; R L Masiero; C E Levy; M S Gomes; L Cui; K Hiramatsu; E M Mamizuka
Journal:  Infect Control Hosp Epidemiol       Date:  2001-07       Impact factor: 3.254

8.  Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus.

Authors:  J E Finan; G L Archer; M J Pucci; M W Climo
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus.

Authors:  Longzhu Cui; Xiaoxue Ma; Katsuhiro Sato; Keiko Okuma; Fred C Tenover; Elsa M Mamizuka; Curtis G Gemmell; Mi-Na Kim; Marie-Cecile Ploy; N El-Solh; Vivian Ferraz; Keiichi Hiramatsu
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

10.  Structure and function of cytidine monophosphate kinase from Yersinia pseudotuberculosis, essential for virulence but not for survival.

Authors:  Nicola J Walker; Elizabeth A Clark; Donna C Ford; Helen L Bullifent; Erin V McAlister; Melanie L Duffield; K Ravi Acharya; Petra C F Oyston
Journal:  Open Biol       Date:  2012-12-05       Impact factor: 6.411

View more
  23 in total

1.  Mutation landscape of acquired cross-resistance to glycopeptide and β-lactam antibiotics in Enterococcus faecium.

Authors:  Emmanuelle Sacco; Mélanie Cortes; Nathalie Josseaume; Christiane Bouchier; Vincent Dubée; Jean-Emmanuel Hugonnet; Jean-Luc Mainardi; Louis B Rice; Michel Arthur
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

2.  "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.

Authors:  Michie Saito; Yuki Katayama; Tomomi Hishinuma; Akira Iwamoto; Yoshifumi Aiba; Kyoko Kuwahara-Arai; Longzhu Cui; Miki Matsuo; Nanae Aritaka; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

3.  Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America.

Authors:  Betsy E Castro; Maritza Berrio; Monica L Vargas; Lina P Carvajal; Lina V Millan; Rafael Rios; Angie K Hernandez; Sandra Rincon; Paola Cubides; Erika Forero; An Dinh; Carlos Seas; Jose M Munita; Cesar A Arias; Jinnethe Reyes; Lorena Diaz
Journal:  J Antimicrob Chemother       Date:  2020-09-01       Impact factor: 5.790

4.  A mutation of RNA polymerase β' subunit (RpoC) converts heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) into "slow VISA".

Authors:  Miki Matsuo; Tomomi Hishinuma; Yuki Katayama; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

Review 5.  Mechanisms of vancomycin resistance in Staphylococcus aureus.

Authors:  Susana Gardete; Alexander Tomasz
Journal:  J Clin Invest       Date:  2014-07-01       Impact factor: 14.808

6.  Role of the msaABCR Operon in Cell Wall Biosynthesis, Autolysis, Integrity, and Antibiotic Resistance in Staphylococcus aureus.

Authors:  Bibek G C; Gyan S Sahukhal; Mohamed O Elasri
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

7.  Identification of a Novel Gene Associated with High-Level β-Lactam Resistance in Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Strain Mu3 and Methicillin-Resistant S. aureus Strain N315.

Authors:  Miki Matsuo; Norio Yamamoto; Tomomi Hishinuma; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

8.  Genome sequence-based discriminator for vancomycin-intermediate Staphylococcus aureus.

Authors:  Lavanya Rishishwar; Robert A Petit; Colleen S Kraft; I King Jordan
Journal:  J Bacteriol       Date:  2013-12-20       Impact factor: 3.490

9.  Metabolic Mitigation of Staphylococcus aureus Vancomycin Intermediate-Level Susceptibility.

Authors:  Stewart G Gardner; Darrell D Marshall; Robert S Daum; Robert Powers; Greg A Somerville
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

10.  Evolution of resistance to a last-resort antibiotic in Staphylococcus aureus via bacterial competition.

Authors:  Gudrun Koch; Ana Yepes; Konrad U Förstner; Charlotte Wermser; Stephanie T Stengel; Jennifer Modamio; Knut Ohlsen; Kevin R Foster; Daniel Lopez
Journal:  Cell       Date:  2014-08-28       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.